What’s Next in the Evolution of Standards for Biologics Development

Why It Matters

A unified, adaptable standards framework reduces development redundancy, lowers biosimilar costs, and accelerates market entry for next‑generation biologics, benefiting manufacturers, regulators, and patients worldwide.

Key Takeaways

• USP shifts from product-specific monographs to hybrid platform standards
• Cross‑cutting chapters address glycosylation, aggregation, and residual DNA
• Emerging modalities like mRNA and CGTs need flexible reference materials
• Harmonized standards reduce duplication, lower biosimilar development costs
• Collaborative regulatory engagement essential for global standard adoption

Pulse Analysis

The rapid expansion of biologic therapeutics—from traditional monoclonal antibodies to sophisticated antibody‑drug conjugates, bispecifics, and mRNA vaccines—has outpaced the legacy compendial approach that once sufficed for simpler proteins like insulin. USP’s new strategy acknowledges that a one‑size‑fits‑all monograph is impractical for these diverse modalities. By establishing general chapters that capture shared critical quality attributes—such as glycosylation patterns, aggregation propensity, and residual host‑cell DNA—USP provides a common analytical language that can be applied across product families, facilitating data comparability and reducing the need for each manufacturer to reinvent testing protocols.

At the same time, the agency recognizes that emerging therapies present novel challenges that cannot be addressed solely by broad standards. Cell and gene therapies, for example, involve patient‑specific constructs and complex manufacturing pipelines, while mRNA products require assessment of sequence integrity, purity, and functional delivery performance. USP’s hybrid model introduces emerging standards and analytical reference materials (ARMs) that serve as early benchmarks for assay development. These tools can evolve into full reference standards as scientific consensus and regulatory acceptance mature, ensuring that the standards ecosystem remains responsive to innovation without sacrificing rigor.

For the industry, this evolution promises tangible benefits. Harmonized, flexible standards cut duplicate analytical work, lower development costs, and streamline regulatory submissions, especially for biosimilars seeking global market access. Moreover, a collaborative framework that engages regulators, manufacturers, and academic experts fosters worldwide alignment, reducing regional disparities in product evaluation. As biologics continue to dominate the therapeutic landscape, a dynamic standards infrastructure will be essential to maintain product quality, accelerate patient access, and sustain confidence in the safety and efficacy of cutting‑edge medicines.